Financial HealthCertainty around Xifaxan is critical to the financial health of BHC, and the current legal situation could jeopardize or delay BLCO share distribution.
LitigationBHC announced it is suing a new Xifaxan generic filer, Amneal Pharmaceuticals, which could result in months or years of litigation.
Market RiskPrevious settlements with Teva, Sandoz, and Sun do not fully mitigate the risk as litigation with Norwich remains ongoing and more generics filers could emerge.